50 results about "Bacterial exotoxin" patented technology

An immunotoxin for use in, and a method for treating a subject having a cancer associated with malignant B-lineage cells or an autoimmune condition, are disclosed. The immunotoxin includes (a) an anti-CD19 antibody lacking an Fc fragment, (b) a modified exotoxin A protein having both Domains II and III, but lacking Domain I, and (c) a peptide linker joining the C-terminal end of the antibody to the N-terminal end of the modified exotoxin A protein. The linker is substantially resistant to extracellular cleavage. The modified exotoxin A protein may be further modified to include a C-terminal KDEL sequence (SEQ ID NO: 6) that promotes transport of the protein to the endoplasmic reticulum of cells that have taken up the immunotoxin.

A transcutaneous immunization system delivers antigen to immune cells without perforation of the skin, and induces an immune response in an animal or human. The system uses an adjuvant, preferably an ADP-ribosylating exotoxin, to induce an antigen-specific immune response (e.g., humoral and / or cellular effectors) after transcutaneous application of a formulation containing antigen and adjuvant to intact skin of the animal or human. The efficiency of immunization may be enhanced by adding hydrating agents (e.g., liposomes), penetration enhancers, or occlusive dressings to the transcutaneous delivery system. This system may allow activation of Langerhans cells in the skin, migration of the Langerhans cells to lymph nodes, and antigen presentation.

Addition of a bacterial ADP-ribosylating exotoxin (bARE) to a formulation (e.g., immunogen or vaccine) or a system (e.g., patch or kit) for immunization enhances the immune response in a subject to one or more components of the formulation. Binding of the B subunit of a bARE to ganglioside GM1 of the subject in vivo, however, mediates toxicity and limits the use of native bARE as adjuvants. Mutation or in vitro coupling of the B subunit to ligands such as GM1 inhibits binding to GM1 in vivo, thereby eliminating toxicity but retaining desired adjuvant activity. The use of such detoxified, GM-1 binding deficient exotoxins provides a safe and potent new strategy for development of effective formulation for immunization.

A transcutaneous immunization system delivers antigen to immune cells through the skin, and induces an immune response in an animal or human. For example, a skin-active adjuvant (e.g., an ADP-ribosylating exotoxin) can be used to induce an antigen-specific immune response (e.g., humoral and / or cellular effectors) after transcutaneous application of a dry formulation containing antigen and adjuvant to skin of the animal or human. The dry formulation may be a powder or a unit-dose patch. Use of adjuvant is not required if the antigen is sufficiently antigenic. Transcutaneous immunization may be induced with or without penetration enhancement.

The field of the present invention relates, in part, to a strategy for novel pharmaceutical applications. More specifically, the present invention relates to a genetically detoxified form of Vibrio cholera exotoxin (cholix) and the use of cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics. Importantly, the systems and methods described herein provide for the following: the ability to deliver macromolecule doses without injections; the ability to deliver cargo, such as (but not limited to) siRNA or antisense molecules into intracellular compartments where their activity is required; and the delivery of nanoparticles and dendrimer-based carriers across biological membranes, which otherwise would have been impeded due to the barrier properties of most such membranes.

The present invention relates to a method of inhibiting a toxin in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer having a plurality of pendant acid functional groups which are directly attached to the polymer backbone or attached to the polymer backbone by a spacer group. The spacer group can have a length in the range from 0 to about 20 atoms. The toxin is, typically, an exotoxin secreted by a pathogenic microorganism, such as a bacterium.

The invention provides chimeric proteins comprising a non-toxic Pseudomonas exotoxin A sequence and a Type IV pilin loop sequence, wherein the Type IV loop sequence is inserted within the non-toxic Pseudomonas exotoxin A. The invention also provides polynucleotides encoding the chimeric proteins, and compositions comprising the polynucleotides or the chimeric proteins. The invention also provides methods for using the chimeric proteins, polynucleotides and compositions of the invention.

Disclosed are methods and compositions for the inhibition of modulation of T cell costimulatory pathway by a pathogenic agent, particularly, the inhibition of activation of a T cell costimulatory pathway, preferably, the CD28 / B7 pathway, by a pyrogenic exotoxin. The method of the invention is based on the inhibition of the direct interaction of a superantigen with a specific site within the dimer interface of a CD28 family member, using immunomodulatory peptides. Further disclosed are specific antagonist immunomodulatory peptides comprising an amino acid sequence derived from a dimer interface of a T cell co-stimulatory pathway member, or peptides which comprise an amino acid sequence which specifically binds to an amino acid sequence within the dimer interface of a T cell co-stimulatory pathway member. Compositions comprising said peptides and methods for the treatment of immune-related disorders are also disclosed. Also disclosed is the use of the CD28 molecule or any fragment thereof comprising the sAg binding site in a method of screening for a test substance which specifically binds to the CD28 molecule and is capable of antagonizing pyrogenic exotoxin-mediated activation of Th1 lymphocytes.

The present invention is directed to a method for delivering exogenous proteins to the cytosol, by binding a target antigen (such as a protein) to a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferably, the target antigen is fused to the transport factor. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from B. anthracis, consisting of amino acids 1-255, preferably a fragment of at least 80 amino acids that shows at least 80% homology to LFn, and a fragment of about 105 amino acids from the carboxy portion that does not bind PA. The target antigen can include any molecule for which it would be desirable to elicit a CMI response, including viral antigens and tumor antigens.

The invention belongs to the technical field of biomedicine, relating to a clostridium difficile exotoxin A carboxy-terminal gene sequence with optimized codon and a nucleic acid vaccine thereof. The codon optimized gene sequence gives consideration to use preferences of mammalian cells and Esherichia coli codon, and the related clostridium difficile vaccine is composed of exotoxin A carboxy-terminal gene sequence with optimized codon and eukaryon expression vector pJW4303. The clostridium difficile exotoxin A carboxy-terminal gene segment optimized by codon can not only be used for constructing nucleic acid vaccines, effectively stimulating host immune system after immunizing mammals, generating better humoral immunity reaction, being applicable to conduct pronucleus expression in esherichia coli, and laying a foundation for acquiring protein in great quantities.

A subunit vaccine for aquaculture comprises an antigen fusion protein, and appropriate carriers or adjuvants. From amino terminal to carboxyl terminal, the antigen fusion protein comprises domain I and domain II of Pseudomonas aeruginosa exotoxin A; a viral antigenic protein producing a fish disease; and a signal peptide of a protein.

The structures of Edema Factor alone and Edema Factor bound to calmodulin without substrate has been crystallized and its structure determined by x-ray crystallography. Based upon these crystal structures, a method assaying for inhibitors of infection by a bacteria is presented which comprises obtaining a potential inhibitor, obtaining a calmodulin activated adenylyl cyclase exotoxin, obtaining calmodulin, admixing the potential inhibitor, the exotoxin, and the calmodulin, and assaying to determine whether or not the potential inhibitor inhibits production of cAMP by exotoxin.

This invention includes fusion proteins comprising a bacterial ADP-ribosylating exotoxin (bARE), or a variant or portion thereof, fused to a STa exotoxin, or a portion or variant thereof. Optionally, the exotoxins are fused via a peptide linker. The invention also includes compositions formulated for transcutaneous immunizations and / or induction of an immune response by epicutaneous administration comprising an effective amount of a fusion protein comprising a bacterial ADP-ribosylating exotoxin fused to a STa exotoxin. Optionally, the exotoxins are fused via a peptide linker.

Pseudomonas exotoxin A or “PE” is a 66 kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38 kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.

The invention discloses a production method of bacterial exotoxin, comprising the procedures of bacterial toxin production culture, bacterial exotoxin extraction, bacterial exotoxin purification and bacterial exotoxin preservation, wherein the bacterial toxin production culture is carried out in a microorganism dialysis incubator which comprises a culture medium chamber and a culture chamber, a dialysis membrane and a dialysis membrane supporting and protecting device are arranged between the culture medium chamber and the culture chamber, the ratio of the volume of the culture medium chamber to the total volume of the culture chamber is selected between 3:1 and 1:6 according to a microorganism culture time, and facilities needed by microorganism growth are arranged in the culture medium chamber. The production method comprises the procedures of toxin production culture, sterilization, filtration, concentration, precipitation, percrystallization and preservation. The production method of bacterial exotoxin is adopted to produce toxin, optimizes bacterial growth environment, simplifies the technologies of concentration and purification of bacterial exotoxin, increases the yield to 90 percent from 17-33 percent, and shortens the purification time to about 12-24 hours from the original natural dialysis of 12-15 days.

The present invention discloses a use of N-acetyl-D-glucosamine or pharmaceutically acceptable salts thereof in the manufacture of a medicament for treating local lesions or systematic symptoms caused by infections of virus or bacteria. A parenteral preparation comprising N-acetyl-D-glucosamine or pharmaceutically acceptable salts thereof as active component is capable of controlling systematic toxic symptoms caused by infections of virus and bacteria and local and systematic lesions caused by endotoxins and exotoxins, and exhibits an excellence rate of 90%.

The invention provides a bispecific molecule comprising an antibody that binds a C3b-like to one or more antigen-binding antibody fragments, each of which binds an antigenic molecule. The invention also provides methods of producing such bispecific molecules and to therapeutic uses of such bispecific molecules. The invention further provides bispecific molecules in which the antigen-binding antibody fragment binds the protective antigen protein of Bacillus anthracis (Anthrax) exotoxin for treatment of Anthrax infection.

The present invention is directed to a method for promoting or stimulating a cell-mediated immune response to an antigen, by administering a target antigen (such as a protein) with a transport factor that contains a fragment of a bipartite protein exotoxin, but not the corresponding protective antigen. Preferred transport factors include the protective antigen binding domain of lethal factor (LFn) from B. anthracis, consisting of amino acids 1-255, preferably a fragment of at least 80 amino acids that shows at least 80% homology to LFn, and a fragment of about 105 amino acids from the carboxy portion that does not bind PA. The target antigen can include any molecule for which it would be desirable to elicit a CMI response, including viral antigens and tumor antigens.

A transcutaneous immunization system delivers antigen to immune cells without perforation of the skin, and induces an immune response in an animal or human. The system uses an adjuvant, preferably an ADP-ribosylating exotoxin, to induce an antigen-specific immune response (e.g., humoral and / or cellular effectors) after transcutaneous application of a formulation containing antigen and adjuvant to intact skin of the animal or human. The efficiency of immunization may be enhanced by adding hydrating agents (e.g., liposomes), penetration enhancers, or occlusive dressings to the transcutaneous delivery system. This system may allow activation of Langerhans cells in the skin, migration of the Langerhans cells to lymph nodes, and antigen presentation.

The present invention relates to a nucleic acid aptamer ETA01 of Pseudomonas aeruginosa exotoxin A and its application. The sequence of the nucleic acid aptamer ETA01 includes: 5'-TGCAACTCCAACTAACCATGTGTTCAT CTGAGGGTGGTCTTCGCA-3'. The nucleic acid aptamer ETA01 of the present invention can bind to Pseudomonas aeruginosa exotoxin A with high affinity and high specificity, and use the nucleic acid aptamer ETA01 as the recognition element of Pseudomonas aeruginosa exotoxin A to establish Pseudomonas aeruginosa The detection method of bacterial exotoxin A, the preparation of detection reagents, and the development of exotoxin A antagonistic drugs can be used in the diagnosis and treatment of Pseudomonas aeruginosa infection and the research on the biological function of Pseudomonas aeruginosa exotoxin A. The method has the advantages of simplicity, rapidity and good characteristics.

The invention discloses quick-dry hand disinfection fluid for viruses on children. The quick-dry hand disinfection fluid comprises, by weight, 0.1%-0.2% of hydrogen peroxide, 50%-60% of medicinal alcohol, 1.0%-1.5% of PEG-7 (polypropylene glycol-7) glyceryl coconate, 0.01%-0.05% of sodium hyaluronate, 0.001%-0.005% of green tea extract, 0.2%-0.5% of sorbitan monostearate, 1.0%-1.5% of medical glycerin, an appropriate quantity of citric acid and the balance purified water. The quick-dry hand disinfection fluid has the advantages that the green tea extract of the quick-dry hand disinfection fluid contains abundant tea polyphenol, accordingly, clostridium botulinum and spores can be killed, the activity of bacterial exotoxin can be inhibited, and antibacterial effects can be realized for diversified pathogens which can cause diarrhea and respiratory tract and skin infection; the quick-dry hand disinfection fluid comprises the sodium hyaluronate which is a natural moisture retention lubricant, and accordingly skin injury due to the quick-dry hand disinfection fluid can be reduced to a great extent; the viruses can be quickly killed by the quick-dry hand disinfection fluid in a formulaafter hands are dried, bacteria can be inhibited in a long-acting manner for 6 hours, skin can be efficiently protected, and the quick-dry hand disinfection fluid in the weak acidity formula is good in fusion property with the skin.